DETAILED ACTION
Applicant’s response filed 9/15/2026 has been fully considered. Email communications have been made of record by being uploaded into DAV. The following rejections and/or objections are either reiterated or newly applied.
The supplemental reply filed on 09/30/2026 is not entered because supplemental replies are not entered as a matter of right except as provided in 37 CFR 1.111(a)(2)(ii). The supplemental reply was not entered before the Examiner considered the prior reply. Furthermore, the supplemental reply is clearly not limited to placement of the application in condition for allowance.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
Claims 8 and 14 are cancelled by Applicant.
Claims 1-7, 9-13 and 15-20 are currently pending and are herein under examination.
Claims 1-7, 9-13 and 15-20 are rejected.
Claim 1 is objected to.
Priority
The instant application claims domestic benefit to U.S. Provisional Application No. 63/775,222, filed 20 March 2025. The claim to domestic benefit is acknowledged. As such, the effective filing date for claims 1-7, 9-13 and 15-20 is 20 March 2025.
Information Disclosure Statement
The IDS filed 09/15/2026 follows the provisions of 37 CFR 1.97 and has been considered in full. A signed copy of the list of references cited from the IDS is included with this Office Action.
Drawings
The objection to the drawings is withdrawn. The drawings filed 3/19/2026 are accepted.
Withdrawn Rejections
35 USC 112(a)
The rejection of claims 1-20 under 35 USC 112(a) is withdrawn in view of claim amendments.
35 USC 112(b)
The rejection of claims 1-20 under 35 USC 112(b) is withdrawn in view of claim amendments.
35 USC 103
The following rejections under 35 USC 103 are withdrawn in view of claim amendment: claims 1-7, 13-15 and 20 for being unpatentable over Maher in view of Mu et al.; claim 12 is for being unpatentable over Maher in view of Mu et al. and in further view of Ding et al.; claims 16-18 for being unpatentable over Maher in view of Mu et al. and in further view of Peneder et al.; and claim 19 for being unpatentable over Maher in view of Mu et al. and Peneder et al. and in further view of Nandrajog.
Claim Objections
The objection to claims 1-4, 9, 11, 15, 17 and 20 are withdrawn in view of claim amendments.
Claim 1 is objected to because of the following informality: claim 1, pg. 5, line 7, should recite “models; [[and]]”. Appropriate correction is required.
Claim Rejections - 35 USC § 112
35 USC 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 5-6 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
This rejection is newly recited as necessitated by claim amendment. Claims dependent from a rejected claim are also rejected unless otherwise noted.
Claim 5, line 3, recites “the whole genome bisulfite sequencing.” It’s unclear which bisulfite sequencing is referenced because claim 1 , pg. 5, lines 11-12, recites “whole genome bisulfite sequencing one or more biological samples”, claim 1, pg. 6, lines 6-7, recites “whole genome bisulfite sequencing of a set of calibration samples”, and claim 1, pg. 6, lines 9-11, recites “the whole genome bisulfite sequencing of … the training samples”. Clarify which sequencing data is referenced.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-7, 9-13 and 15-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more.
Any newly recited portions herein are necessitated by claim amendment.
Step 1:
Step 1 asks whether the claims recite statutory subject matter. In the instant application, claims 1-7, 9-13 and 15-20 recite a method. As such, these claims recite statutory subject matter (Step 1: YES).
Step 2A, Prong 1:
Claims that recite statutory subject matter are analyzed under Step 2A, Prong 1 to determine if they recite any concepts that equate to an abstract idea, law of nature or natural phenomena. The instant claims recite the following limitations that equate to one or more categories of judicial exception:
Claim 1 recites “and a multiplicity of classification models, wherein: each classification model of the multiplicity of classification models comprises: a health condition; input features, wherein each input feature of the input features comprises: a methylation percentage associated with a portion of a genome; and a genome region containing the portion of the genome, wherein the genome region corresponds to a region of whole genome bisulfite sequencing data; an output comprising a probability that a patient has the health condition; training samples, wherein each training sample of the training samples comprises: a sample patient; the input features associated with the sample patient; and a label indicating whether the sample patient has the health condition; and a machine learning model trained on the training samples to calculate the output from the input features; … select one or more classification models from the multiplicity of classification models based on the context information as one or more selected classification models; and identify selected regions of a genome as a union of genome regions associated with all input features associated with the one or more selected classification models; … selectively process the methylation data by reading only base addresses in the methylation data associated with said union of genome regions; for each selected region of the selected regions, aggregate the methylation data at the base addresses within said selected region by adding methylated read counts of the base addresses within said selected region and dividing by total read counts of the base addresses within the selected region to calculate a region-level methylation percentage for said selected region; and for each selected classification model of the one or more selected classification models: translate the region-level methylation percentage for each selected region corresponding to the each selected classification model into a value that is compatible with the training samples associated with the each selected classification model, by adjusting the region-level methylation percentage for a difference between the whole genome bisulfite sequencing of the one or more biological samples from the subject patient and whole genome bisulfite sequencing of a set of calibration samples; and further adjusting the region-level methylation percentage for a difference between the whole genome bisulfite sequencing of the set of calibration samples and the training samples associated with the selected classification model, to yield patient feature values for the input features associated with the each selected classification model; and input the patient feature values associated with said each selected classification model into the each selected classification model to calculate a probability that the subject patient has the health condition associated with the each selected classification model.”
Claim 2 recites “apply one or more rules to each probability that is calculated for said each selected classification model, to generate conclusions about health status of the subject patient.”
Claim 3 recites “wherein: the one or more selected classification models comprise a plurality of selected classification models; and … generate a union of binary verdicts from said plurality of selected classification models as said conclusions about health status of the subject patient.”
Claim 4 recites “wherein: the machine learning model of said each classification model comprises one or more of: XGBoost; a decision tree; a random forest; logistic regression; and a neural network.”
Claim 7 recites “wherein: when the portion of the genome associated with an input feature of a classification model comprises a single base address, the genome region containing the portion of the genome comprises a contiguous region of a plurality of base addresses that contains the single base address.”
Claim 9 recites “said adjusting by: calculating a patient average methylation percentage in one or more biologically invariant regions from the whole genome bisulfite sequencing of the one or more biological samples from the subject patient; calculating a calibration average methylation percentage in the one or more biologically invariant regions from the whole genome bisulfite sequencing of the set of calibration samples; and adding a difference between the calibration average methylation percentage and the patient average methylation percentage to the region-level methylation percentage for each selected region.”
Claim 10 recites “when said difference between the calibration average methylation percentage and the patient average methylation percentage is greater than a valid range of values, mark the whole genome bisulfite sequencing of one or more biological samples from the subject patient as invalid.”
Claim 11 recites “said further adjusting by: calculating a calibration average methylation percentage for each selected region from the whole genome bisulfite sequencing of the set of calibration samples; calculating, for the each selected classification model, a training set average methylation percentage for each selected region corresponding to the each selected classification model from training samples associated with sample patients that do not have the health condition associated with said each selected classification model; and adding a difference between the training set average methylation percentage and the calibration average methylation percentage to the region-level methylation percentage for each selected region.”
Claim 12 recites “wherein: the training samples associated with at least one classification model of the multiplicity of classification models comprises additional training samples from a different classification model of the multiplicity of classification models, wherein sample patients associated with the additional training samples have the health condition associated with the different classification model and are labelled as not having the health condition associated with the at least one classification model.”
Claim 13 recites “selectively process the methylation data
Claim 15 recites “select a fragmentomics model; execute the fragmentomics model to calculate one or more fragmentomics feature values from said whole genome bisulfite sequencing of one or more biological samples from the subject patient; and apply said one or more rules to each probability that is calculated for said each selected classification model and to said one or more fragmentomics feature values”
Claim 16 recites “wherein said one or more fragmentomics feature values comprise: a measure of a ratio of short fragments to long fragments in said whole genome bisulfite sequencing of one or more biological samples from the subject patient.”
Claim 17 recites “execute said fragmentomics model to divide a human genome into one or more series of genome bins; and said measure of the ratio of short fragments to long fragments comprises a number of said one or more series of genome bins wherein a normalized z-score of a ratio of short fragments to long fragments within a genome bin exceeds a threshold value.”
Claim 18 recites “calculate said normalized z-score using a mean value and a standard deviation value within said genome bin calculated using genome data from a set of healthy patients.”
Claim 19 recites “calculate said normalized z-score further using a floor value for said standard deviation value within said genome bin.”Claim 20 recites “one or more additional models trained on said archive database; wherein: one or more of said one or more additional models is configured to use one or more new features extracted from whole genome bisulfite sequencing data that represent previously unknown biomarkers for health conditions associated with the one or more of said one or more additional models.”
Limitations reciting a mental process.
Claims 1-4, 7-13 and 15-20 contain limitations recited at such a high level of generality that they equate to a mental process because they are similar to the concepts of collecting information, analyzing it, and displaying certain results of the collection and analysis in Electric Power Group, LLC, v. Alstom (830 F.3d 1350, 119 USPQ2d 1739 (Fed. Cir. 2016)), which the courts have identified as concepts that can be practically performed in the human mind. The paragraphs below discuss the broadest reasonable interpretation (BRI) of the limitations in these claims that recite a mental process.
Regarding claims 1 and 3-4, a multiplicity of classification models includes collecting data related to the models such as a logistic regression. Selecting models and identifying genome regions shared across the selected models includes making a selection based on data and determining which genome regions are shared amongst the input features. Selectively processing the methylation data includes parsing out data that is not associated with the union of regions. Aggregating methylation data to calculate a methylation percentage includes performing calculations recited in specification para. [78]. Translating methylation percentages into a value includes performing calculations recited in claims 9 and 11. Inputting values into a model to calculate probabilities includes performing calculations using a logistic regression.
Claims 2-3 and 15 include following the steps recited in Figure 12 and aggregating data. Claims 9 and 11 include a human performing calculations using pen and paper. Claim 10 includes organizing and modifying data. Claim 13 includes extracting information through analysis. Claims 16-19 recite performing calculations which can be performed on pen and paper. Claim 17 divides a genome into bins which includes parsing a genome based on genomic coordinates. Claim 20 recites using models which includes performing calculations using a logistic regression.
Limitations reciting a mathematical concept.
Claims 1, 4, 9, 11 and 15-20 recite limitations that equate to a mathematical concept because they are similar to the concepts of organizing and manipulating information through mathematical correlations in Digitech Image Techs., LLC v Electronics for Imaging, Inc. (758 F.3d 1344, 111 U.S.P.Q.2d 1717 (Fed. Cir. 2014)), which the courts have identified as mathematical concepts. The paragraphs below discuss the broadest reasonable interpretation (BRI) of the limitations in these claims that recite a mathematical concept.
Claims 1 and 4 recite trained machine learning models that can be logistic regressions, which recite functions. Claim 1 recites calculating methylation percentages, and adjusting for a difference between values, and inputting values into a model to calculate probabilities. Claims 1, 9 and 11 recite translating methylation percentages into a value using mathematical concepts. Claims 15-17 recites calculating fragmentomic feature values which are a measure of a ratio and normalized z-score of a ratio. Claims 18-19 recite calculations and equations. Claim 20 recites additional models which includes claiming a logistic regression.
Limitations included in the recited judicial exception.
Claims 7 and 12 further limit the data collected in claim 1 related to the classification models, and thus also equate to gathering data.
As such, claims 1-7, 9-13 and 15-20 recite an abstract idea (Step 2A, Prong 1: YES).
Additional Elements:
Once limitations have been identified that recite a judicial exception, the claims are evaluated for additional elements. The additional elements are then analyzed under Step 2A, Prong 2 then Step 2B. The instant claims recite the following additional elements:
Claim 1 recites “A medium-depth whole genome bisulfite sequencing analysis system that integrates classification models trained on disparate datasets, comprising: one or more processors; wherein the one or more processors are configured to: receive context information associated with a subject patient, comprising one or more of: health data associated with the subject patient; demographic data associated with the subject patient; and clinician orders associated with the subject patient … receive methylation data generated by whole genome bisulfite sequencing of one or more biological samples from the subject patient;”
Claims 2-7, 9-13 and 15-20 recite “The medium-depth whole genome bisulfite sequencing analysis system that integrates classification models trained on disparate datasets”.
Claims 2-3, 9-11, 15 and 17-19 recite “wherein the one or more processors are further configured to: …”
Claim 5 recites “the whole genome bisulfite sequencing comprises medium-depth sequencing.”
Claim 6 recites “the medium-depth sequencing comprises sequencing depth between l0x and
30x, inclusive.”
Claim 20 recites “an archive database comprising whole genome bisulfite sequencing data generated from one or more biological samples from a multiplicity of patients;”
These above recited additional elements are analyzed below under both Step 2A, Prong 2 and Step 2B:
Step 2A, Prong 2:
Claims found to recite a judicial exception under Step 2A, Prong 1 are then further analyzed to determine if the claims as a whole integrate the recited judicial exception into a practical application or not (Step 2A, Prong 2). The judicial exception is not integrated into a practical application because the claims do not recite additional elements that reflect an improvement to a computer, technology, or technical field (MPEP § 2106.04(d)(1) and 2106.5(a)), require a particular treatment or prophylaxis for a disease or medical condition (MPEP § 2106.04(d)(2)), implement the recited judicial exception with a particular machine that is integral to the claim (MPEP § 2106.05(b)), effect a transformation or reduction of a particular article to a different state or thing (MPEP § 2106.05(c)), nor provide some other meaningful limitation (MPEP § 2106.05(e)). Rather, the claims include limitations that equate to an equivalent of the words “apply it” and/or to instructions to implement an abstract idea on a computer (MPEP § 2106.05(f)), insignificant extra-solution activity (MPEP § 2106.05(g)), and field of use limitations (MPEP § 2106.05(h)). The paragraphs below discuss the additional elements recited above in the instant claims.
Claims 1-7, 9-13 and 15-20 recite a system comprising one or more processors. There are no limitations requiring anything other than a generic computer. Therefore, these limitations equate to mere instructions to implement an abstract idea on a generic computer, which the courts have established does not render an abstract idea eligible in Alice Corp. 573 U.S. at 223, 110 USPQ2d at 1983. These limitations also invoke a computer as a tool to perform tasks such as receive, store and transmit data, which equates to extra-solution activity (MPEP 2106.05(f)(2)).
Claims 1 and 5-6 recite receiving context information and receiving methylation data generated by medium-depth bisulfite sequencing which equate to insignificant extra-solution activity of necessary data gathering (MPEP § 2106.05(g)(3)). These limitations gather data necessary to perform the judicial exception in claim 1 of selecting models from the classification models based on context information and calculating methylation percentages.
Claim 20 recites an archive database which equates to insignificant extract solution activity because it is nominally related to the invention of calculating methylation percentages (MPEP 2106.05(g)(2)). It also invokes a computer as a tool to store data, which equates to extra-solution activity (MPEP 2106.05(f)(2)).
As such, claims 1-7, 9-13 and 15-20 are directed to an abstract idea (Step 2A, Prong 2: NO).
Step 2B:
Claims found to be directed to a judicial exception are then further evaluated to determine if the claims recite an inventive concept that provides significantly more than the judicial exception itself (Step 2B). These claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because these claims recite additional elements that equate to instructions to apply the recited exception in a generic way and/or in a generic computing environment (MPEP § 2106.05(f)) and to well-understood, routine and conventional (WURC) limitations (MPEP § 2106.05(d)). The paragraphs below discuss the additional elements recited above in the instant claims.
Claims 1-7, 9-13 and 15-20 recite a system comprising one or more processors. There are no limitations that these components require anything other than a generic computer and/or generic computing system. Therefore, these limitations equate to instructions to implement an abstract idea on a generic computing environment, which the courts have established does not provide an inventive concept in Intellectual Ventures I LLC v. Capital One Bank (USA), 792 F.3d 1363, 1367, 115 USPQ2d 1636, 1639 (Fed. Cir. 2015).
Claims 1 and 5-6 recite receiving context information and receiving methylation data generated by medium-depth bisulfite sequencing. These limitations equate to receiving/transmitting data over a network, which the courts have established as WURC limitation of a generic computer in buySAFE, Inc. v. Google, Inc., 765 F.3d 1350, 1355, 112 USPQ2d 1093, 1096 (Fed. Cir. 2014).
Claim 20 recites an archive database which equates to storing information in memory, which the courts have established as a WURC function of a generic computer in Versata Dev. Group, Inc. v. SAP Am., Inc., 793 F.3d 1306, 1334, 115 USPQ2d 1681, 1701 (Fed. Cir. 2015).
When these additional elements are considered individually and in combination, they do not provide an inventive concept because they equate to WURC functions/components of a generic computer and equate to mere instructions to implement an abstract idea on a generic computer. Therefore, these additional elements do not transform the claimed judicial exception into a patent-eligible application of the judicial exception and do not amount to significantly more than the judicial exception itself (Step 2B: No).
As such, claims 1-7, 9-13 and 15-20 are not patent eligible.
Response to Arguments under 35 USC 101
Applicant's arguments filed 9/15/2026 have been fully considered but they are not persuasive.
Applicant appears to assert that claim 1 does not recite an abstract idea (pg. 22, para. 9 – pg. 26, para. 3). Applicant’s argument is not persuasive because:
Claim 1 recites at least the mental process of making a selection of classification models by analyzing data comprising context information. Claim 1 recites at least a mathematical concept of calculating methylation percentages, which recites math rather than involving or being based on math. Applicant also appears to make remarks regarding a practical application, which are addressed in the responses below.
Applicant’s arguments regarding selective processing of large WGBS datasets to reduce processing time and expense are not persuasive because (pg. 25, para. 1 – pg. 26, para. 1) (pg. 26, para. 6 – pg. 27, para. 5):
The claims have not been limited to using hundreds of gigabytes of WGBS data. Claim 1 limitations of selecting models based on context information, identifying a union of genome regions, and selectively processing the methylation data recite abstract ideas. MPEP 2106.05(a) recites “the judicial exception alone cannot provide the improvement.” Claim 1 limitations of receiving context information and methylation data recite insignificant, extra-solution actively of necessary data gathering (MPEP 2106.05(g)(3)). They gather data necessary to perform the abstract ideas of selecting models, identifying regions of a genome, and processing the methylation data.
Applicant argues a practical application associated with calculating methylation percentages from medium-depth WGBS and that a two-stage adjustment enables use of WGBS data with models trained on disparate datasets (pg. 27, para. 5 – pg. 29, para. 5). Applicant’s arguments are not persuasive because:
Integration into a practical application is evaluated by: “(1) identifying whether there are any additional elements recited in the claim beyond the judicial exception(s); and (2) evaluating those additional elements individually and in combination to determine whether they integrate the exception into a practical application” (MPEP 2106.04(d).II). Additionally, MPEP 2106.04(d).III recites “the way in which the additional elements use or interact with the exception may integrate it into a practical application.”
All the alleged improvements in this section appear to be derived from claim 1 limitation of selectively processing the methylation data, aggregating the methylation data, and translating region level methylation percentages by adjusting. However, these limitations recite an abstract idea. MPEP 2106.05(a) recites “the judicial exception alone cannot provide the improvement.” Furthermore, the improvement is in the abstract idea itself of analyzing methylation data rather than an improvement in WGBS. Nothing about the technological field of WGBS is improved. MPEP 2106.05(a) recites “an improvement in the abstract idea itself (e.g. a recited fundamental economic concept) is not an improvement in technology.” Moreover, the claims have not been limited to liquid biopsies, and there is no limitation that the classification models in claim 1 are trained on disparate datasets.
Even if system claim 1 recited a sequencer configured to produce the methylation data received by the processor, this would equate to a "recitation with respect to the manner in which a claimed apparatus [i.e., sequencer] is intended to be employed”, and “[a]pparatus claims cover what a device is, not what a device does” (MPEP 2114.II). Thus, a medium depth sequencer configured to sequence at a particular medium depth does not limit the structure of the sequencer and would recite an intended use. It appears that for the sequencer and its particular medium depth to be considered as additional elements together, claim 1 would have to be a method with an active step of sequencing at medium depth. However, this would equate to data gathering because it provides the necessary methylation data to perform the improved abstract idea of methylation data analysis, wherein the sequencer itself has not been improved.
Applicant asserts that the claims recite a technological improvement, and any mathematical concept is integrated into a practical application (pg. 29, para. 6 – pg. 30, para. 3) Applicant’s argument is not persuasive because:
As described in the responses above, the claims are directed to an abstract idea, and any alleged improvement appears to be a result of the judicial exception itself, which does not integrate into a practical application (MPEP 2106.05(a)).
Applicant argues that receiving WGBS data does not equate to mere data gathering activity (pg. 30, para. 4 – last para.). Applicant’s argument is not persuasive:
Receiving methylation data by the processors recites necessary data gathering activity because it gathers the data necessary to perform the abstract ideas of selectively processing the methylation data, aggregating methylation data to calculate methylation percentages, and adjusting percentages. Mere data gathering does not provide a practical application or significantly more (MPEP 2106.05(g)).
Applicant argues under Step 2B that claim 1 does not append generic processors to mathematical calculations, the claims must be considered individually and as combination, and mentions certain technological benefits (pg. 31, para. 1-5). Applicant’s argument is not persuasive because:
As discussed in responses above, any alleged improvement in technology is a result of the judicial exception itself, which is not an improvement in technology (MPEP 2106.05(a)). Also, claim 1 uses generic computer processors to receive data and to perform abstract ideas. This equates to mere instructions to implement an abstract idea on a generic computer, and equates to invoking a generic computer as a tool to perform an existing process such as receiving data, both of which do not provide significantly more (MPEP 2106.05(f)).
When the additional elements of claim 1 are viewed individually and in combination, they equate to instructions to implement an abstract idea on a generic computer and to receiving/transmitting data over a network, both of which do not provide significantly more. Also, the abstract idea is not considered under Step 2B for conventionality, only additional elements.
Applicant argues that the archive database of claim 20 does not equate to merely storing data in memory or insignificant extra-solution activity (pg. 32, para. 1). Applicant’s argument is not persuasive because:
The archive database is so broadly recited that its BRI includes storing data in memory, which is not an inventive concept. See Versata Dev. Group, Inc. v. SAP Am., Inc., 793 F.3d 1306, 1334, 115 USPQ2d 1681, 1701 (Fed. Cir. 2015). The additional models previously trained on the WGBS data are generically configured “to use” new features. There is no description of what the use is. Regardless, the additional models themselves recite an abstract idea. Thus, the archive gathers data used by the additional models, which equates to necessary data gathering (MPEP 2106.05(f)).
Applicant asserts that the translating step in claim 1 is not WURC and that it confers an improvement of allowing previously collected data to be reused with a WGBS system with trained models (pg. 31, last para.) (pg. 32, para. 2). Applicant’s argument is not persuasive because only additional elements are evaluated for their conventionality. The translating step in claim 1 recites an abstract idea and thus does not provide an inventive concept.
Applicant’s remarks regarding claims 2-7, 9-13 and 15-20 are not persuasive for the same reasons applied in the above responses because they further define the abstract ideas but do not provide a practical application of significantly more (pg. 32, para. 3 – pg. 33, para. 3).
Conclusion
No claims are allowed.
Claims 1-7, 9-13 and 15-20 are free from the prior art because Applicant incorporated the limitations of previously recited claim 8 into amended claim 1. Amended claim 1 is free from the prior art for the same reasons applied to previously recited claim 8 in the conclusion of the previous Office action.
Notable, but not relied upon, prior art included Gross et al. (US 2021/0313006 A1) cancer classification with genomic region modeling.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Noah A. Auger whose telephone number is (703)756-4518. The examiner can normally be reached M-F 7:30-4:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Karlheinz Skowronek can be reached at (571) 272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/N.A.A./Examiner, Art Unit 1687
/KAITLYN L MINCHELLA/Primary Examiner, Art Unit 1685